



## BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

May 5, 2022

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will participate in three upcoming investor conferences. Dr. Mehta will highlight the Company's neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. He will also discuss the Company's commercial and launch readiness plans for IGALMI™ (dexmedetomidine) sublingual film.

Presentation Details:

**Event:** BofA Securities 2022 Healthcare Conference\*

**Date:** Thursday, May 12, 2022

**Time:** 11:00 AM ET / 8:00 AM PT

**Event:** UBS Global Healthcare Conference 2022\*

**Date:** Monday, May 23, 2022

**Time:** 10:00 AM ET

**Event:** H.C. Wainwright Global Investment Conference

**Date:** Wednesday, May 25, 2022

**Time:** 3:00 PM ET

To access live webcasts of the fireside chats and presentation, and any accompanying presentation materials, please visit "News/Events" within the Investors & Media section of the Company's website at [www.bioxceltherapeutics.com](http://www.bioxceltherapeutics.com) beginning 15 minutes prior to the start time of the presentation. A replay of the webcast will be available on the Company's website following the event.

\*Fireside chat format

### About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company's commercial product, IGALMI™ (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. BXCL501 is also being evaluated for the acute treatment of agitation associated with Alzheimer's disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia and, under its subsidiary OnkosXcel Therapeutics, BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit [www.bioxceltherapeutics.com](http://www.bioxceltherapeutics.com).

### Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the date, time and content of the Company's presentations at the BofA Securities 2022 Healthcare Conference, the UBS Global Healthcare Conference 2022, and the H.C. Wainwright Global Investment Conference. When used herein, words including "anticipate," "will," "plan," "may," "continue," "intend," "designed," "goal" and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2021, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at [www.sec.gov](http://www.sec.gov). These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Contact Information

### Corporate

BioXcel Therapeutics  
Erik Kopp

1.203.494.7062

[ekopp@biocelltherapeutics.com](mailto:ekopp@biocelltherapeutics.com)

**Investor Relations**

FTI Consulting

Matt Ventimiglia

1.212.850.5624

[matthew.ventimiglia@fticonsulting.com](mailto:matthew.ventimiglia@fticonsulting.com)

**Media**

FTI Consulting

Helen O'Gorman

1.718.408.0800

[helen.ogorman@fticonsulting.com](mailto:helen.ogorman@fticonsulting.com)

Source: BioXcel Therapeutics, Inc.